» Articles » PMID: 35891431

Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice Against DENV2

Abstract

The occurrence of dengue disease has increased radically in recent decades. Previously, we constructed the pE1D2 and pcTPANS1 DNA vaccines encoding the DENV2 envelope (E) and non-structural 1 (NS1) proteins, respectively. To decrease the number of plasmids in a tetravalent candidate vaccine, we constructed a bicistronic plasmid, pNS1/E/D2, encoding these two proteins simultaneously. We evaluated the protective immunity induced in mice vaccinated with the pNS1/E/D2 candidate and compared to the responses elicited by immunization with the former vaccines isolated or in combination. We transfected BHK-21 cells with the different plasmids and detected recombinant proteins by immunofluorescence and mass spectrometry assays to confirm antigen expression. BALB/c mice were inoculated with the DNA vaccines followed by a lethal DENV2 challenge. ELISA, PRNT50, and IFN-gamma ELISPOT assays were performed for the investigation of the humoral and cellular responses. We observed the concomitant expression of NS1 and E proteins in pNS1/E/D2-transfected cells. All E-based vaccines induced anti-E and neutralizing antibodies. However, anti-NS1 antibodies were only observed after immunization with the pcTPANS1 administered alone or combined with pE1D2. In contrast, splenocytes from pNS1/E/D2- or pcTPANS1 + pE1D2-vaccinated animals responded to NS1- and E-derived synthetic peptides. All the DNA vaccines conferred protection against DENV2.

Citing Articles

Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.

Bello M, Alsaadi A, Naeem A, Almahboub S, Bosaeed M, Aljedani S Front Immunol. 2025; 15():1475886.

PMID: 39840044 PMC: 11747009. DOI: 10.3389/fimmu.2024.1475886.


Multi-epitope peptide vaccines targeting dengue virus serotype 2 created via immunoinformatic analysis.

Morgan R, Ismail N, Alshahrani M, Aboshanab K Sci Rep. 2024; 14(1):17645.

PMID: 39085250 PMC: 11291903. DOI: 10.1038/s41598-024-67553-1.


Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy.

Kok B, Lim H, Lim C, Lai N, Leow C, Leow C Virus Res. 2022; 324:199018.

PMID: 36493993 PMC: 10194131. DOI: 10.1016/j.virusres.2022.199018.

References
1.
Zellweger R, Tang W, Eddy W, King K, Sanchez M, Shresta S . CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. J Virol. 2015; 89(12):6494-505. PMC: 4474296. DOI: 10.1128/JVI.00036-15. View

2.
Gao G, Wang Q, Dai Z, Calcedo R, Sun X, Li G . Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Gene Ther. 2008; 19(9):927-36. DOI: 10.1089/hum.2008.011. View

3.
Whiteman M, Li L, Wicker J, Kinney R, Huang C, Beasley D . Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine. 2009; 28(4):1075-83. DOI: 10.1016/j.vaccine.2009.10.112. View

4.
Zhang W, Chipman P, Corver J, Johnson P, Zhang Y, Mukhopadhyay S . Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol. 2003; 10(11):907-12. PMC: 4148076. DOI: 10.1038/nsb990. View

5.
Gubler D . Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998; 11(3):480-96. PMC: 88892. DOI: 10.1128/CMR.11.3.480. View